These GLP-1 RAs and DPP-4is significantly reduced cardiovascular risk factors, including blood glucose levels, hemoglobin A1c (HbA1c), fasting blood glucose (FBG), body weight, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C), compared with placebo or conventional treatment [71] Additionally, dulaglutide, when included in standard antihyperglycemic therapy for patients without documented cardiovascular disease, lowered the risk of cardiovascular events [72]. Here, GLP1R is linked to cardiovascular disorder.